The adverse effects of xanthene are related to the theophylline levels in the blood and include brain damage.

Choice A rationale

Exhibiting the ability to provide self-care may not be realistic for a patient with advanced Alzheimer’s disease. Cognitive decline may impair their ability to perform daily activities independently, necessitating assistance from caregivers.

Choice B rationale

Improving memory for recent events is unlikely in advanced Alzheimer’s disease, as the condition typically involves progressive memory loss and cognitive decline. New medications may help manage symptoms, but reversing memory loss is not a realistic goal.

Choice C rationale

Receiving appropriate assistance for care needs is a realistic and achievable goal for patients with advanced Alzheimer’s disease. As the disease progresses, patients will require increasing levels of support to ensure their safety and well-being.

Choice D rationale

Demonstrating improved cognitive function is unlikely in advanced Alzheimer’s disease. While medications may help manage symptoms, the progressive nature of the disease means that cognitive decline will continue, and improvement is not a realistic expectation.

Choice A rationale

It is not correct to say that women are more prone to adverse effects from medications than men. Adverse effects can vary based on individual responses, and gender is not the sole determinant.

Choice B rationale

Women of reproductive age are often excluded from early-phase drug trials due to the potential risks that experimental drugs could pose to developing fetuses. The reproductive risk needs to be carefully managed to avoid harm.

Choice C rationale

While it is true that drugs can affect women differently than men, this answer does not directly address the specific reason why women are excluded from Phase 1 studies, which is primarily due to the potential risks to reproductive health.

Choice D rationale

This is incorrect because drugs are not tested only on men because they are stronger. This statement is not scientifically accurate and does not reflect the principles of clinical trial design.